The Gcgr−/− mice and the human patient with Mahvash disease strongly suggest that complete inhibition of glucagon signaling as a therapeutic approach to treat type 2 diabetes may have limited clinical potential due to safety concerns. This evidence concerns the gene GCG and type 2 diabetes mellitus.